Celera Genomics Presents Preclinical Data on its Human Histone Deacetylase (HDAC) Inhibitor

20-Apr-2005

Celera Genomics Group, an Applera Corporation business, presented preclinical data characterizing its novel histone deacetylase (HDAC) inhibitor, CRA-024781, as a cancer therapeutic, describing its dose-dependent inhibition of tubulin and histone Acetylation and significant anti-tumor activity in multiple in vivo tumor xenograft models. In addition, it was demonstrated that the measurement of tubulin and histone acetylation might be used to monitor the pharmacodynamic effects of CRA-024781 in vivo. These findings support the application of CRA 024781 in anti cancer therapy.

These studies follow the first report of the crystal structure of the enzyme HDAC8 that was published by Celera Genomics in the journal Structure in July 2004. Knowledge of the three-dimensional structure of HDAC has guided synthetic activities of novel inhibitors of HDAC at Celera Genomics.

"We're pleased with the progress we've made in advancing our HDAC inhibitor through these preclinical experiments," said Robert Booth, Ph.D., Chief Scientific Officer of Celera Genomics. "Now that we have developed a better understanding of the pharmocodynamics of this compound, and barring any unforeseen obstacles, we anticipate that this compound will enter the clinic over the coming months."

Histone deacetylation is carried out by a family of related HDAC enzymes and causes changes to chromatin structure and to gene expression patterns. HDAC inhibition reverses some of these changes and can inhibit the proliferation of cancer cells, and in some cases, can specifically induce cancer cell death. These data have fueled the design of small-molecule inhibitors of HDAC that are currently undergoing testing as potential treatments for major human diseases, including cancer.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

New 'Chiral Vortex' of Light Reveals Molecular Mirror Images - The entirely new structure of light could help drug developers see their work more clearly than before

New 'Chiral Vortex' of Light Reveals Molecular Mirror Images - The entirely new structure of light could help drug developers see their work more clearly than before

Category:Canola_diseases

Measuring glucose concentration without enzymes - Sensor of novel material an alternative for blood glucose measurement

Measuring glucose concentration without enzymes - Sensor of novel material an alternative for blood glucose measurement

Univar Czech s.r.o. acquires enzymes distribution business of Ekozym

Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms - 'South-South' biotech collaborations boost health, economies: Study

Nanostructures in human teeth

Nanostructures in human teeth

Additional Data from Multiple Phase 1 and 2 Studies of S*BIO’s Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis - SB1518 Alleviates MF-Associated Splenomegaly and Shows No Myelosuppression and No Exacerbation of Cytopenias

Signs of dementia are written in the blood - 33 metabolic compounds linked to dementia could be key to new methods of diagnosis and treatment

Signs of dementia are written in the blood - 33 metabolic compounds linked to dementia could be key to new methods of diagnosis and treatment

Blood brain barrier gateway found

European Commision approves Amgen´s KINERET® for the treatment of rheumatoid arthritis - First Interleukin-1 receptor antagonist represents new way to treat RA

Evotec Enters into Long-Term Focused Library Agreement with Almirall - Value Exceeding EUR 2.5 m over the Two-Year Contract Period

Why gold nanoparticles can penetrate cell walls - Gold nanoparticles with special coatings can deliver drugs or biosensors to a cell's interior without damaging it